Author:
Dolton Michael J.,Chiang Po-Chang,Ma Fang,Jin Jin Y.,Chen Yuan
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88–110.
2. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–62.
3. Grimstein M, Yang Y, Zhang X, Grillo J, Huang S-M, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration’s Office of Clinical Pharmacology. J Pharm Sci. 2019;108(1):21–5.
4. ERIVEDGE (vismodegib) capsules, for oral use. Highlights of prescribing information. 2019 [18 February 2020]; Available from: https://www.gene.com/download/pdf/erivedge_prescribing.pdf.
5. European Medicines Agency. Annex I Summary of product characteristics. Erivedge 150 mg hard capsules. [cited 2019 18 February 2020]; Available from: https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献